Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

August 18, 2015. This 56-week, randomized, double-blind, placebo-controlled, parallel-group trial was performed to evaluate the safety of liraglutide (1.8 mg/day or 3.0 mg/day) vs placebo for weight management in overweight or obese adults with type 2 diabetes. Inclusion criteria were body mass index ≥27.0 kg/m2, age ≥18 years, taking 0 to 3 oral diabetes agents (metformin, thiazolidinedione, sulfonylurea), and with A1C levels ranging from 7.0% to 10.0%. The study had 3 co-primary endpoints: relative weight change and proportion of participants losing ≥5% or >10% of initial body weight. Patients (N=846) were recruited from 126 sites in 9 countries. Investigators found that patients receiving liraglutide 3.0 mg had a mean 6.4 kg weight loss (6.0% of body weight), compared with 5.0 kg (4.7%) for liraglutide 1.8 mg, and 2.2 kg (2.0%) for placebo. The proportion of patients experiencing weight loss ≥5% of baseline body weight was 54.3% with liraglutide 3.0 mg, 40.4% with liraglutide 1.8 mg, and 21.4% with placebo. The proportion with weight loss >10% was 25.2% with liraglutide 3.0 mg, 15.9% with liraglutide 1.8 mg, and 6.7% with placebo. You can follow this link to read the study abstract.